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Abstract
Introduction Insulin analog glargine (GLA) has been
available as one of the therapeutic options for patients with
type 1 diabetes mellitus to enhance glycemic control.
Studies have shown that a decrease in the frequency of
hypoglycemic episodes improves the quality of life (QoL)
of diabetic patients. However, there are appreciable
acquisition cost differences between different insulins.
Consequently, there is a need to assess their impact on QoL
to provide future guidance to health authorities.
Method A systematic review of multiple databases
including Medline, LILACS, Cochrane, and EMBASE
databases with several combinations of agreed terms
involving randomized controlled trials and cohorts, as well
as manual searches and gray literature, was undertaken.
The primary outcome measure was a change in QoL. The
quality of the studies and the risk of bias was also assessed.
Results Eight studies were eventually included in the
systematic review out of 634 publications. Eight different
QoL instruments were used (two generic, two mixed, and
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four specific), in which the Diabetes Treatment Satisfaction
Questionnaire (DTSQ) was the most used. The systematic
review did not consistently show any significant difference
overall in QoL scores, whether as part of subsets or com-
bined into a single score, with the use of GLA versus
neutral protamine Hagedorn (NPH) insulin. Only in patient
satisfaction measured by DTSQ was a better result con-
sistently seen with GLA versus NPH insulin, but not using
the Well-being Inquiry for Diabetics (WED) scale. How-
ever, none of the cohort studies scored a maximum on the
Newcastle–Ottawa scale for quality, and they generally
were of moderate quality with bias in the studies.
Conclusion There was no consistent difference in QoL or
patient-reported outcomes when the findings from the eight
studies were collated. In view of this, we believe the cur-
rent price differential between GLA and NPH insulin in
Brazil cannot be justified by these findings.
Key Points for Decision Makers
In Brazil, insulin glargine (GLA) has been available
as a treatment option versus neutral protamine
Hagedorn (NPH) insulin for a number of years to
enhance glycemic control and patients’ quality of life
as an easier preparation to administer than NPH
insulin.
A systematic review failed to consistently show any
significant difference in quality of life scores
between GLA versus NPH insulin. Only in patients’
satisfaction measured by the Diabetes Treatment
Satisfaction Questionnaire was a better result
consistently seen with GLA versus NPH insulin.
However, there were concerns with the quality of the
studies.
Based on our findings, we believe the current price
differential between the two insulin preparations in
Brazil cannot be justified within its universal
healthcare system.
1 Introduction
Diabetes mellitus (DM) is a chronic and complex disease
that requires continuous medical care. DM can be subdi-
vided into several etiological types, with Type 1 DM
(T1DM) and Type 2 DM (T2DM) being the most prevalent
[1]. T1DM is characterized by the destruction of the islets
of Langerhans and insulin-secreting b1 cells in the
pancreas mediated by the immune response, and its treat-
ment is based on the replacement of deficient or non-ex-
istent insulin [2].
There are a range of insulins currently available for the
treatment of patients with T1DM. These include both neutral
protamine Hagedorn (NPH), which has an intermediate
action profile, and longer-acting insulins such as analog
glargine (GLA). NPH is usually the first-choice treatment
when the diagnosis of T1DM is confirmed in view of typi-
cally appreciably lower costs than the analogs, and similar
effectiveness [3–7]. GLA was developed as a better alter-
native to basal insulin, aiming for a peak-free preparation and
with prolonged action, which mimics the insulin secretion of
individuals without DM. This has resulted in a decrease in
episodes of hypoglycemia as well as better glycemic control,
mainly glycated hemoglobin (HbA1c), compared with NPH
insulin in some publications [8–12], with HbA1c the main
predictor of the effectiveness of T1DM treatment. The
monitoring and maintenance of HbA1c at levelsB 7% is
fundamental to reducing chronic microvascular (retinopa-
thy, nephropathy, and neuropathy) and macrovascular
complications (peripheral arterial disease, carotid disease,
and coronary artery disease), as well as acute complications,
which includes episodes of hypoglycemia and hyper-
glycemia associated with T1DM [2, 13].
However, in two systematic reviews (SRs), no benefits for
GLA compared with NPH insulin were found for the main
outcome measure, HbA1c, in terms of effectiveness as well
as safety [4, 14]. Similar results were seen in a recent cohort
study in Brazil [15]. The difference in the findings may partly
be due to the study sponsors, with studies with conflicts of
interest favoring GLA versus those studies without conflicts
of interest [14]. Another important aspect is the price dif-
ference that can exist between GLA and NPH insulin. In the
state of Minas Gerais, Brazil, there was an increase of just
under 300% in the costs of insulins to the State’s Department
of Health after the incorporation of GLA. This resulted in
approximately US$6 million being spent on insulins in 2012,
exacerbated by the price difference between NPH and GLA
in Brazil at over 500% [4, 15].
Improved quality of life (QoL), defined by the World
Health Organization (WHO) as a way of measuring the
individual’s perception of their life position, cultural
aspects, personal goals, and concerns [16], is fundamental
to understanding the notion of health. Consequently, this is
an important variable in clinical practice, as well as helping
with decisions on priority setting and resource allocation.
The measurement of the impact of different treatments on
QoL, as well as its improvement, is one of the expected
humanistic results of healthcare practices and public poli-
cies in the fields of health promotion and disease preven-
tion, especially chronic diseases such as T1DM [16, 17].
Several instruments have been used to evaluate the impact
P. H. R. F. Almeida et al.
of different treatments on the QoL of patients with diabetes
[18]. Effective control of T1DM, and minimal problems
with insulin therapy, tend to favorably influence patients’
QoL [19–22].
It is hypothesized that the use of GLA versus NPH
insulin would promote better QoL, as GLA insulin could
lead to a decrease in the episodes of hypoglycemia and
would also cause less discomfort to patients. There have
been several SRs to assess differences in effectiveness and
safety of GLA versus NPH insulins [14, 23–25]. However,
we did not identify any SRs in the literature measuring the
impact on patients’ QoL as a primary outcome, although
our unit and others have assessed the impact of T1DM on
patients’ health-related QoL (HRQoL) [17]. In addition, we
are aware that Plank et al. [23], in their SR, also assessed
the impact of the different insulins on patients’ QoL but
found no evidence of an improvement in patients’ scores
with GLA versus NPH insulins with the instruments used.
Vardi et al. [24] in their SR for the Cochrane Collaboration
showed higher scores in patient satisfaction favoring GLA;
however, when using the Audit of Diabetes-Dependent
Quality-of-Life Questionnaire (ADDQoL) instrument, no
differences were seen between the two insulins. Assessing
the impact of the two insulins on QoL is important given
the current differences in acquisition costs between GLA
and NPH insulin in Brazil, and the need to maximize health
gain within finite resources in the current economic situa-
tion. Consequently, we aimed to evaluate the impact on
QoL of T1DM patients using either GLA or NPH insulin
through an SR of randomized clinical trials (RCTs) and
observational studies. The findings will be used to further
guide pricing and other strategies for insulins in Brazil to
help maximize the use of available resources for these
patients. Within Brazil, CONITEC (The national Com-
mittee for Health Technology Incorporation) currently
assess the potential listing and funding of new medicines
based on their relative efficacy, safety, costs, and budget
impact versus current standards in all or defined popula-
tions. This is based on published evidence. Subsequently,
at the state level, committees including the Commission of
Pharmaceuticals and Therapeutics (Comissa˜o de Farma´cia
e Terapeˆutica–CFT) in Minas Gerais, further evaluate their
relative value versus current standards for inclusion within
state-wide agreed treatment guidance, with prescribing
against the agreed guidance subsequently monitored [4].
2 Methods
An SR of the literature was undertaken according to the
methodological guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA)
[26]. SRs are seen as important for scientific research as
they typically reflect the best evidence on a topic, with the
findings subsequently used to improve treatments and
policy decisions where pertinent.
The SR protocol for this study was registered in the
PROSPERO database (International Prospecting Register
of Ongoing Systematic Reviews) under n8
CRD42016046875 (https://www.crd.york.ac.uk/
PROSPERO/display_reord.asp?ID=CRD42016046875).
2.1 Databases and Search Strategy
Available publications were selected until January 2017 in
the following databases: MEDLINE (PubMed), Latin
American and Caribbean Literature in Health Sciences
(LILACS), Cochrane Library, and EMBASE. Several
combinations of terms were used following the PICO
(population, intervention, comparison and outcome) strat-
egy: T1DM, GLA, NPH and QoL (Table 1). As a com-
plement to the electronic search, a manual search was
carried out in all included studies, as well as in the peri-
odicals Diabetes Care and Quality of Life Research, in the
years 2000 to December 2016, by two independent
reviewers. A search of studies in the gray literature was
also carried out in the Digital Library of the Federal
University of Minas Gerais (UFMG), and in the thesis and
dissertations bank of the Coordination of Improvement of
Personnel of Higher Education (CAPES) and the Brazilian
Digital Library of Theses and Dissertations. Table 1
describes the overview of the search strategy based on the
Medline (PubMed) database, with more details contained
in Appendix 1 (see electronic supplementary material).
Key terms included T1DM, GLA, NPH, and QoL.
2.2 Selection of Studies and Eligibility Criteria
RCTs and cohort studies (prospective and retrospective)
were subsequently selected for the SR from the papers
identified that assessed the impact of GLA versus NPH
insulin on patients’ QoL.
We excluded cohort studies and RCTs that did not con-
centrate on QoL as the primary outcome measure, studies
with oral hypoglycemic medicines concomitant with insulin
in patients with T1DM, as well as studies with a sample of 30
individuals or less or that had a follow-up time of\4 weeks.
4 weeks was considered the minimum time to effectively
measure the impact of different treatments on patients’ QoL
based on an earlier study from our group [14].
2.3 Data Collection and Analysis
Initially, the recovered studies in the databases were allo-
cated on a single basis to exclude those duplicated by the
EndNote software. Thereafter, two independent reviewers
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(PA and TS) evaluated the titles (Phase 1), the abstracts
(phase 2) and the full text (phase 3). A third reviewer (VA)
was asked to solve possible discordances. Sociodemo-
graphic characteristics of the patients, treatment period,
and QoL were extracted in duplicate in a form, previously
formulated and tested in Excel, for this purpose. A quali-
tative synthesis of the studies was performed, since the
heterogeneity of the measurement instruments and the data
did not make a quantitative synthesis possible as under-
taken with previous SRs concentrating on issues such as
effectiveness when measuring HbA1c levels and hypo-
glycemic episodes [14, 23–25].
The methodological quality of the cohort studies was
evaluated using the Newcastle–Ottawa scale. This scale
was originally developed to evaluate the quality of obser-
vational studies. It contains eight items. These include
representativeness of the sample in the exposed cohort,
selection of the unexposed cohort, exposure by the type of
measure used (e.g., secure records or structured inter-
views), how the outcome of interest was assessed, whether
the follow-up of the study was long enough for the
hypothesis of the results to occur, and if there was adequate
follow-up of the cohorts. Stars are assigned to each com-
pleted item, with the highest possible score being nine. A
score above six means that the study has high method-
ological quality [27].
In order to assess the risk of bias in RCTs, the current
recommendation of the Cochrane Collaboration is to use
the Revman software (Review Manager 5.3). This program
consists of two parts, in which seven domains are dis-
tributed: random sequence generation, concealment of
allocation, blinding of participants and professionals,
incomplete outcomes, reporting of outcome, and other
sources of bias [28]. The sources of funding for the iden-
tified studies were examined for potential sources of bias,
as the influence of this on the findings and their
Table 1 Search strategies used to undertake the systematic review
Electronic
databases
Search strategy Recovered
studies
Medline
(PubMed)
((((((((((((((((((Diabetic Ketoacidosis[MeSH Terms]) OR Diabetes Mellitus, Type 1[MeSH Terms]) OR
Diabetes Mellitus, Insulin*Dependent[Text Word]) OR Insulin-Dependent Diabetes Mellitus[Text Word])
OR Juvenile-Onset Diabetes Mellitus[Text Word]) OR Type 1 Diabetes Mellitus[Text Word]) OR Sudden-
Onset Diabetes Mellitus[Text Word]) OR Diabetes Mellitus, Type I[Text Word]) OR IDDM[Text Word])
OR Insulin*Dependent Diabetes Mellitus 1[Text Word]) OR Juvenile*Onset Diabetes[Text Word]) OR
Brittle Diabetes Mellitus[Text Word]) OR Ketosis-Prone Diabetes Mellitus[Text Word]) OR Diabetes,
Autoimmune[All Fields] AND Text Word) OR Autoimmune Diabetes[Text Word]) NOT diabetes
insipidus[MeSH Terms])) AND (((((((Insulin, Isophane[MeSH Terms]) OR Isophane Insulin[Text Word])
OR NPH Insulin[Text Word]) OR NPH[Text Word]) OR Protamine Hagedorn Insulin[Text Word]) OR
Neutral Protamine Hagedorn Insulin[Text Word]))) OR (((((((LY2963016 insulin glargine [Supplementary
Concept]OR glargine[Text Word]) OR lantus[Text Word]) OR insulin glargine[Text Word]) OR
HOE*901[Text Word])) OR ‘‘Insulin, Long-Acting’’[Mesh])) AND (((((((((((((((((((((((((((((((((((((‘‘quality
of life’’[MeSH Terms]) OR ‘‘quality of life’’[Text Word]) OR ‘‘life qualities’’[Text Word]) OR ‘‘life
quality’’[Text Word]) OR ‘‘health related quality of life’’[Text Word]) OR ‘‘qol’’[Text Word]) OR
‘‘hrqol’’[Text Word]) OR ‘‘hrqol’’[Text Word]) OR ((‘‘quality of well being scale self administered’’[Text
Word] OR ‘‘quality of well being scale self administeredqwbsa’’[Text Word]))) OR ‘‘qwb-sa’’[Text Word])
OR ‘‘euroqol’’[Text Word]) OR ‘‘Eq 5d’’[Text Word]) OR ‘‘Eq 5d 3 l’’[Text Word]) OR ‘‘the medical
outcomes study 36 item short form health survey’’[Text Word]) OR ‘‘sf 36’’[Text Word]) OR ‘‘world health
organization quality of life’’[Text Word]) OR ((‘‘whoqol’’[Text Word] OR ‘‘whoqol 100’’[Text Word] OR
‘‘whoqolbref’’[Text Word] OR ‘‘whoqolbref questionnaire’’[Text Word]))) OR ‘‘quality adjusted life
years’’[Text Word]) OR ‘‘qalys’’[Text Word]) OR ‘‘nottingham health profile’’[Text Word]) OR ((‘‘sickness
impact profile’’[Text Word] OR ‘‘sickness impact profile sip’’[Text Word]))) OR ‘‘dartmouth coop’’[Text
Word]) OR ‘‘hrql’’[Text Word]) OR ‘‘health utilities index’’[Text Word]) OR ‘‘hui’’[Text Word]) OR ‘‘short
form 6d’’[Text Word]) OR ‘‘sf 6d’’[Text Word]) OR ((‘‘diabetes 39’’[Text Word] OR ‘‘diabetes 39
questionnaire’’[Text Word]))) OR ((‘‘diabetes quality of life measure’’[Text Word] OR ‘‘diabetes quality of
life questionnaire’’[Text Word]))) OR ‘‘dqol’’[Text Word]) OR ((‘‘audit of diabetes dependent quality of
life’’[Text Word] OR ‘‘audit of diabetes dependent quality of life addq’’[Text Word]))) OR ((‘‘addqol’’[Text
Word] OR ‘‘addqol questionnaire’’[Text Word]))) OR ‘‘diabetes attitude scale’’[Text Word]) OR ‘‘diabetes
knowledge test’’[Text Word]) OR ((‘‘diabetes empowerment scale’’[Text Word] OR ‘‘diabetes
empowerment scale short’’[Text Word] OR ‘‘diabetes empowerment scale short form’’[Text Word]))) OR
((‘‘michigan neuropathy screening instrument’’[Text Word] OR ‘‘michigan neuropathy screening instrument
questionnaire’’[Text Word]))) OR ((‘‘diabetes treatment satisfaction questionnaire’’[Text Word] OR
‘‘diabetes treatment satisfaction questionnaire score’’[Text Word] OR ‘‘diabetes treatment satisfaction
questionnaire scores’’[Text Word] OR ‘‘diabetes treatment satisfaction questionnaire status’’[Text Word]
OR ‘‘diabetes treatment satisfaction questionnaire status version’’[Text Word])))
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implications was seen in a previous SR comparing the
different insulin types [14]. Comments regarding any
conflict of interest, study financing by a manufacturer of
any of the insulins, or if any of the authors were related to
the pharmaceutical industry or had received fees from
them, were examined and documented.
2.4 Quality-of-Life Scales
A number of QoL scales have been used in the literature to
assess the impact of different treatment options on patients’
QoL in studies, including both generic and disease-specific
instruments. The most prevalent scales used for studies
assessing the QoL of patients with diabetes include:
• The mixed Well-Being Questionnaire 28 (W-BQ28),
which has the following domains: positive perception
of well-being, negative perception of well-being,
energy, and stress. For the specific part, these included
positive perception of well-being related to DM,
negative perception of well-being related to DM, and
stress related to DM [29, 30].
• The Well-Being Questionnaire (WBQ22), which pro-
vides a general welfare score comprising 22 items and
has the following domains: depression, anxiety, energy,
and positive perception of well-being. There is also
WBQ12, which is a shortened version of WBQ22 with
12 items and four domains: negative well-being,
energy, positive well-being, and general well-being
[30].
• The Diabetes Treatment Satisfaction Questionnaire
(DTSQ). The DTSQs instrument evaluates treatment
satisfaction at the beginning, with DTSQc used at the
end of follow-up. DTSQ presents three domains:
satisfaction with current treatment, perceived frequency
of hypoglycemia, and perceived frequency of hyper-
glycemia. DTSQc uses the same domains as DTSQs,
but it has different response options and asks respon-
dents to assess changes in current treatment satisfaction
(endpoint) compared with baseline in order to over-
come a possible ceiling effect [31].
• The Well-being Inquiry for Diabetics (WED) evaluates
four areas of psychological well-being: (a) somatic
symptoms related to diabetes and physical functioning;
(b) concerns related to diabetes and emotional state;
(c) mental health; (d) family relationships, friends
network, and society [32].
• The Diabetes Quality of Life Measure (DQOL) presents
four domains: impact, satisfaction, concerns about DM,
and concerns about social and vocational life [33].
• The Audit of Diabetes-Dependent Quality-of-Life
Questionnaire (ADDQoL), an instrument that has four
domains: social and professional life, average weighted
impact (AWI), specific QoL for DM, and current QoL
that refers to the overall score [34].
3 Results
3.1 Study Selection for the Systematic Review
We found 634 publications in the electronic databases
(Fig. 1). After exclusion of 99 duplicates, 535 articles were
selected for title and abstract analysis. Of these, 513 pub-
lications were subsequently excluded for a variety of rea-
sons (Fig. 1), resulting in 22 publications for complete
reading. Manual searches, which included analyzing all
volumes and chosen periodicals page by page without the
help of any search engine and checking all references in the
SRs, did not return any relevant further studies for inclu-
sion. Finally, 8 studies with 11 publications (9 papers and 2
conference abstracts) remained for the SR (Fig. 1). Studies
were excluded mainly because they included patients with
T2DM; used insulins other than GLA and NPH, or con-
centrated on oral antidiabetics alone, or patients were
taking these concomitantly with injectable insulins; were
not cohorts or RCTs; or did not use any instrument to
measure QoL.
3.2 Study Characteristics
From the eight included studies, four cohorts [35–38]
(two retrospective [35, 38], two prospective studies
[36, 37]) and four RCTs [39–42] were identified that met
our criteria (Fig. 1). The follow-up time of patients in
these eight studies ranged from 6 to 24 months; three
cohort studies [35–37] had a long follow-up period
(12 months or more) and one [38] had an intermediate
time (6–12 months). All RCTs [39–42] had a long fol-
low-up time ([12 months). Three studies [35, 37, 39]
reported no conflicts of interest and five [36, 38, 40–42]
declared a conflict of interest with pharmaceutical
companies funding the studies or fee-paying the authors.
The studies evaluated approximately 1855 individuals to
compare the QoL among patients with T1DM who used
either GLA or NPH insulin.
Concerning the characteristics of individuals with
T1DM in the identified studies, patients’ ages ranged from
5 to 40 years, on average. Two studies evaluated the QoL
of pediatric individuals [35, 38] and six analyzed the
impact of the different insulin preparations on the QoL of
adult patients [36, 37, 39–42]. The studies had a majority
of men, with the duration of T1DM ranging from 2.9
(SD± 0.2) to 22.3 (SD± 15.5) years (Table 2).
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3.3 Methodological Quality
None of the cohort studies scored a maximum of nine stars
on the Newcastle–Ottawa scale, and in general, the studies
obtained only a moderate quality score (Table 2). In
addition, none of the studies had a low risk of bias in all
seven domains. In the second domain, about allocation
concealment, all studies had a high risk of bias, since the
insulin bottles were identifiable. For the third and fourth
domains, on blinding of participants, professionals, and
evaluators, all studies had a high risk of bias (open-label).
Only one study blinded the data raters. Regarding the sixth
domain, about reporting of selective outcomes, one study
did not report in the protocol that the QoL of patients
would be collected in the Electronic case records, being
considered a high risk of bias. The others were judged as
having insufficient information. In the seventh domain,
dealing with other sources of bias, all the studies had some
kind of link with the pharmaceutical industry, declared or
otherwise, being considered a high risk of bias. In general,
the four RCTs had poor methodological quality (Fig. 2).
3.4 Data Synthesis
The eight studies used eight instruments, in total, to eval-
uate the QoL of patients with T1DM comparing GLA and
NPH insulins. Two generic instruments were used in the
studies. These included W-BQ28 (mixed character) [36],
and WBQ22 (generic) [40]. Four specific instruments were
used to measure the QoL of patients with T1DM. These
included the DTSQs and DTSQc [35, 36, 40–42], DQOL
[38], and the ADDQol [42], with a mixed scale—the WED
scale [37] —as well.
3.5 Findings
We will principally document the impact of the different
insulin preparations on QoL with key details incorporated
into Tables 2 and 3, which include the study design, study
population and numbers, the QoL instruments used and
their scores, any conflicts of interest, study duration, and
the quality of the studies.
In the study by Pa¨iva¨rinta et al. [35], there was no sta-
tistical difference between the insulins using the DTSQs.
There was also no statistically significant difference in
HbA1c levels between the two insulins.
Gallen and Carter [36] observed differences between
baseline and the endpoints in some of the parameters
studied using W-BQ28 and DTSQs, including well-being
and energy, favoring GLA. The other domains showed no
differences in the QoL of GLA compared with NPH
insulin. When the DTSQs instrument was used, a statisti-
cally significant difference in satisfaction between the
treatments was observed. In the other domains, no
Fig. 1 Overview of the
flowchart of the selection of
included studies
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difference in QoL was observed between GLA and NPH.
Overall, GLA had a significantly favorable impact on
HbA1c compared with NPH insulins.
Manini et al. [37] found a statistically significant dif-
ference in favor of GLA insulin in three out of the four
domains of the QoL scale (WED) used: symptoms, dis-
comfort, and impact, with the overall total score statisti-
cally favoring GLA. A statistically significant difference
was also observed for HbA1c favoring GLA (7.6%) com-
pared with NPH insulin (8.4%).
None of the domains in the study of Dixon et al. [38]
using DQOL showed any statistically significant differ-
ences in the scores between GLA and NPH insulin on QoL,
although borderline significance when looking at HbA1c
values.
Only one domain showed a difference in the study of
Bolli et al. [39] using the WED, with no difference seen in
HbA1c values between the two insulins.
In the three instruments used by Witthaus et al. [40], no
statistically significant difference was seen in the domains
of W-BQ12 and W-BQ22. In the DTSQs, a statistically
significant difference was seen in favor of GLA insulin in
two out of the four domains: satisfaction with treatment
and perception of hypoglycemia.
Ashwell et al. [41] found statistically significant differ-
ences in favor of GLA insulin in two out of three domains
in DTSQc, with one not recorded. Similarly, with DTSQc,
there was one statistically significant difference in favor of
GLA insulin with three not recorded. There was also a
significant difference favoring GLA in two out of the three
domains in the ADDQoL. There was also a statistically
significant difference in terms of HbA1c favoring GLA.
Polonsky et al. [42] showed a statistically significant
difference in favor of GLA insulin using the DTSQs in
treatment satisfaction; however, the other domains were
not recorded. No statistical difference was seen with
HbA1c levels.
Fig. 2 Cochrane Collaboration
bias risk graph
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Table 3 Efficacy, effectiveness, and quality of life of included studies
Study and instrument Domains Score p Value HbA1c (%) p Value
NPH GLA NPH GLA
Pa¨iva¨rinta et al. [35]
DTSQs Satisfaction with treatment NR NR NR 8.4 8.4 NS
Hypoglycemia perception NR NR
Perception of hyperglycemia NR NR
Gallen and Carter [36]
W-BQ28 Negative perception of well-being NR NR NS 8.4 7.76 0.006*
Energy NR NR 0.001*
Total well-being NR NR 0.032*
Stress NR NR NS
Negative perception of welfare with DM NR NR NS
Stress related to DM NR NR NS
Diabetes-related positive well-being NR NR 0.006*
DTSQs Satisfaction with treatment 23.7 (SD± 0.85) 28.1 (SD± 0.87) 0.001*
Perception of hypoglycemia NR NR NR
Perception of hyperglycemia NR NR NR
Manini et al. [37]
WED Symptoms 15.3 (SD± 2.7) 16.1 (SD± 2.4) 0.040* 8.4 7.6 0.0001*
Discomfort 13.1 (SD± 3.0) 13.4 (SD± 3.3) 0.019*
Serenity 13.9 (SD± 1.9) 14.5 (SD± 1.5) 0.197
Impact 29.6 (SD± 4.7) 31.1 (SD± 6.1) 0.0002*
Total score 71.9 (SD± 10.7) 75.1 (SD± 11.4) 0.0002*
Dixon et al. [38]
DQOL Total score 1 (SD± 1) 1 (SD± 1) NS 8.3 8.7 0.05
Impact NR NR NR
Satisfaction 1.9 (SD± 0.6) 1.9 (SD± 0.6) NS
Concerned with DM 2.2 (SD± 0,5) 2.2 (SD± 0.5) NS
Bolli et al. [39]
WED Impact 80 (73–85) 77 (73–82) NS 7.26 7.26 NS
Satisfaction 32 (27–38) 31 (27–35) NS
General worries 32 (27–38) 32 (27–34) NS
Diabetes-related worries 31 (25–34) 32 (27–34) 0.05
Witthaus et al. [40]
DTSQs Satisfaction with treatment 27.53 29.11 0.001* NR NR NR
Perception of hypoglycemia 2.25 2.20 NS
Perception of hyperglycemia 2.70 2.25 0.038*
W-BQ22 General well-being 50.97 51.56 NS
Depression 3.34 3.31 NS
Anxiety 3.67 3.67 NS
Energy 8.31 8.82 NS
Positive perception of well-being 13.53 13.72 NS
W-BQ12 General well-being 50.52 51.12 NS
Negative perception of well-being NR NR NS
Positive perception of well-being 12.97 13.57 NS
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4 Discussion
The most used instrument to assess the impact of GLA
versus NPH insulin in our SR was the DTSQs
[35, 36, 40–42], similar to Plank et al. [23] and Vardi et al.
[24].
In general, there appeared to be no difference overall in
QoL comparing GLA and NPH insulins when the score of
the domains of the different instruments were evaluated
(Table 3), although significant differences were seen in
favor of GLA insulin in a number of the domains in the
studies by Gallen and Carter [36], Manini et al. [37], Bolli
et al. [39], Witthaus et al. [40], Ashwell et al. [41] and
Polonsky et al. [42]. This is similar to the SRs of Plank
et al. [23] and Vardi et al. [24]. Our findings were also
consistent with the SR performed by Singh et al. [25],
which evaluated QoL as a secondary result of HbA1c
outcome and GLA safety. However, the authors found that
patients preferred treatment with insulin analogs over
human insulins. This appeared to be due to the flexibility in
the dosage between meals and satisfaction with the treat-
ment. There were issues though with the quality of the
assessed studies, with typically only moderate scores on the
Newcastle–Ottawa Scale [27].
Conflicts of interest are a concern if the judgment of
healthcare professionals is influenced by possible financial
gain. There can also be concerns with possible ethical and
bioethical considerations, centering on patients participat-
ing in the research and their well-being [43]. However, we
recognize that this is not always the case. Five of the eight
studies included in this SR reported some conflict of
interest with pharmaceutical companies. These included
Gallen and Carter [36]; Witthaus et al. [40]; Bolli et al.
[39]; Ashwell et al. [41]; and Polonsky et al. [42]. How-
ever, the studies were not totally favorable towards GLA
over NPH insulin, although they recorded domains that
statistically favored GLA insulin. This can be a concern
with one SR reporting that studies with pharmaceutical
company sponsorship had a greater relative risk, approxi-
mately 27%, of publishing outcomes favorable to the
investigated intervention when compared with studies that
had independent sources of funding [44]. Favorable results
towards GLA insulin were also seen in the SR by Marra
et al. [14] in studies sponsored by pharmaceutical compa-
nies versus those studies where there was no such spon-
sorship. It should also be emphasized that QoL is a
subjective measure and that these conflict of interest rela-
tionships between researchers, universities, and
Table 3 continued
Study and instrument Domains Score p Value HbA1c (%) p Value
NPH GLA NPH GLA
Ashwell et al. [41]
DTSQs Satisfaction with treatment 23.7 (SD± 0.7) 32.3 (SD± 0.7) 0.001* 7.5 8.0 0.001*
Perception of hypoglycemia NR NR NR
Perception of hyperglycemia 4.0 (SD± 0.2) 2.7 (SD± 0.2) 0.001
DTSQc Satisfaction with treatment 13.5 (SD± 1.7) - 0.4 (SD± 1.8) 0.001*
Perception of hypoglycemia NR NR NR
Perception of hyperglycemia NR NR NR
ADDQol Social life and work life NR NR NR
Average weighted impact (AWI) - 1.7 (SD± 0.1) - 1.4(SD± 0.1) 0.003*
QoL specific for DM NR NR NR
Current QoL 1.3 (SD± 0.1) 1.6 (SD± 0.1) 0.014
Polonsky et al. [42]
DTSQs Satisfaction with treatment 28.40 29.6 0.006* 7.8 7.9 0.719
Perception of hypoglycemia NR NR NR
Perception of hyperglycemia NR NR NR
ADDQoL Audit of Diabetes Dependent Quality of Life Questionnaire, DM diabetes mellitus, DQOL Diabetes Quality of Life Measure, DTSQ
Diabetes Quality of Life Measure (DTSQs evaluates treatment satisfaction at the beginning with DTSQc measuring it at the end of follow-up),
GLA glargine, NPH neutral protamine Hagedorn, NR not reported, NS not significant, QoL quality of life, SD standard deviation, WBQ22 Well-
Being Questionnaire–22 items (WBQ12 = 12 items), W-BQ28 mixed Well-Being Questionnaire–28, WED Well-Being Inquiry for Diabetics
*p\0.05
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pharmaceutical companies can be persuasive, with the
findings often favoring the funder [44, 45].
5 Limitations
We accept this SR only included cohort studies (prospec-
tive and retrospective), which may have limited study
findings, since this study design has selection bias and
confounding factors that are not controlled. There are also
concerns with the external validity of RCTs. In addition,
RCTs and cohorts were compared, but as no quantitative
analysis was performed, statistical heterogeneity was not a
problem for data comparison, although it made this more
challenging.
Some studies did not present important information,
which impaired a meta-analysis of the QoL instruments
used in the primary studies. There was also considerable
diversity among the instruments used to assess the QoL,
which also precluded a full meta-analysis. Some authors
also used instruments of satisfaction with treatment
(DTSQs) and did not opt for QoL instruments. This is a
concern as QoL is a broader construct, as defined by the
WHO [16], than just satisfaction with the current treatment.
The absence of an appreciable number of papers out of
those initially sourced that treated QoL as a primary end-
point also made the meta-analysis and associated compar-
isons more difficult. Despite these limitations, we believe
our findings are robust and provide guidance to the
authorities in Brazil and other countries where there are
still considerable acquisition cost differences between
GLA and NPH insulins.
6 Conclusion
Despite the limited number of published studies comparing
the QoL of patients with T1DM treated with GLA versus
NPH insulin, we believe our study findings showing a
relative lack of overall difference between the two are
robust. This adds to the current debate about the inclusion
of GLA insulin in the list of official reimbursed medicines
in Brazil whilst there are still considerable acquisition cost
differences. GLA, however, seems to be better accepted by
users in the domain that assessed satisfaction in T1DM
treatment in the DTSQs instrument. However, these find-
ings, which are related to the patient’s therapeutic prefer-
ence, should be viewed with caution and discussed in the
light of other comparisons of GLA versus NPH insulin,
which have principally focused on HbA1c and the safety of
the different insulins. This especially given some of the
concerns with the quality of the reviewed studies coupled
with existing considerable differences in acquisition costs
between the two insulins in Brazil.
In the future, in patients with chronic diseases such as
diabetes, we would like to see more studies assessing the
impact of different treatment approaches on the QoL of
patients as a primary outcome measure. This can help to
formulate appropriate treatment guidelines, including the
place of different therapies in treatment regimens alongside
considerations of effectiveness and safety. As a result,
health authorities will be better able to maximize the health
gain of patients within finite resources. These are consid-
erations for the future.
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